Cardioprotective effects of medical therapy for cancer therapy-related cardiac dysfunction: a systematic review and meta-analysis

Clicks: 3
ID: 323453
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #222 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background - Cancer therapy-related cardiac dysfunction (CTRCD) limits optimal cancer therapy regimens. Although heart failure guideline-recommended medical therapy (GRMT) has been proposed as a cardioprotective strategy, robust evidence from randomized controlled trials (RCTs) remains insufficient due to limited study availability and heterogeneous outcomes. We conducted a comprehensive systematic review and meta-analysis to investigate the cardioprotective potential of GRMT in patients receiving cancer therapy. Methods - EMBASE and PubMed were systematically searched for RCTs evaluating GRMT for the prevention of CTRCD in cancer patients treated with any established anti-cancer drug cocktail. Two independent reviewers performed study selection, data extraction, and risk-of-bias assessment using the Cochrane risk-of-bias 2 (RoB 2) tool. GRMT classes included RAAS inhibitors, beta-blockers, mineralocorticoid antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). Statins were additionally considered. Studies were stratified by cancer treatment: 1) anthracycline-based, 2) anti-HER2-based, and 3) combined anthracycline/anti-HER2 regimens. Primary outcome was a change in left ventricular ejection fraction (LVEF) in patients treated with versus without GRMT. Random-effect meta-analyses were conducted using STATA and presented as weighted mean differences (WMD). Anthracycline-mediated CTRCD data were visualized in the attached forest plots (figure 1). Results - 36 RCTs comprising 3968 patients were included. RAAS-inhibition significantly improved LVEF in anthracycline-mediated (group 1: WMD 3.64; [95% Confidence Interval 0.21 – 7.08]), and anti-HER2-mediated CTRCD (group 2: 4.15 [2.49-5.81]), but not in anthracycline/anti-HER2 regimens (group 3: 0.08 [-1.19-1.36]). Beta-blockers demonstrated a similar pattern (group 1: 1.05 [0.04-2.06]; group 2: 4.01 [2.07-5.96]; group 3: 0.67 [-0.68-2.01]). Statins were associated with a LVEF preservation in group 1 (2.54 [1.51-3.56]), however no claim could be made for group 2, as evidence was limited to a single study. MRAs and combined RAAS-inhibitors/beta-blockers therapies showed protective effects in group 1, although robust conclusions were limited due to sparse numbers of RCTs. No RCT data were available on SGLT2i. Conclusion - RAAS inhibitors and beta-blockers significantly improved LVEF in patients exhibiting anthracycline- or anti-HER2-mediated CTRCD, whereas no beneficial effect was observed in patients with combination regimens. We hypothesize that severity of established CTRCD in this subgroup might be too advanced for significant LVEF improvements. Moreover, statins hold promise in the prevention of anthracycline- and/or anti-HER2-mediated CTRCD. Other GRMT classes, i.e. MRAs and SGLT2i, remain underrepresented in RCTs, despite their potential cardioprotective properties. These findings emphasize the need for future trials focusing on modern HF therapies in oncology patients.GRMT in anthracycline-mediated CTRCD
Reference Key
openalex_W7172249987 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Y Appels, R Parvan, C G S Mohan, L I Yousif, R A De Boer, W C Meijers
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.094
URL
https://doi.org/10.1093/eurheartjsupp/suag097.094
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.